Payment overview · 2025
General Payments
$899.49
46 reported records · 17 companies
Healthcare provider profile · identity verified
Curtis Patrick Craig, MD
Allopathic & Osteopathic Physicians|Family Medicine · WASHINGTON, MI · NPI 1255392361
Verified facts
What the public records show
CMS Open Payments records show Curtis Patrick Craig, MD received $899.49 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $269.25 | 29.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.25 | 15.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.68 | 7.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.82 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.23 | 5.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.63 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.08 | 4.3% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $34.92 | 3.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.43 | 3.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $31.32 | 3.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.51 | 3.4% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $26.01 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.05 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.88 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.51 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.58 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.34 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $899.49 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.30 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $140.25 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $140.25 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.95 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.68 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.23 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.05 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 36 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
146 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
356 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1143 | 294 |
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 277 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 778 | 240 |
| Metoprolol Succinate | Metoprolol Succinate | 663 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 162 |
| Losartan Potassium | Losartan Potassium | 491 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 140 |
| Omeprazole | Omeprazole | 420 | 129 |
| Pravastatin Sodium | Pravastatin Sodium | 367 | 91 |
| Methylprednisolone | Methylprednisolone | 363 | 233 |
| Eliquis | Apixaban | 356 | 90 |
| Furosemide | Furosemide | 350 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 99 |
| Ibandronate Sodium | Ibandronate Sodium | 334 | 96 |
| Famotidine | Famotidine | 330 | 94 |
| Lisinopril | Lisinopril | 323 | 98 |
| Trazodone Hcl | Trazodone Hcl | 316 | 106 |
| Metformin Hcl | Metformin Hcl | 314 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 90 |
| Simvastatin | Simvastatin | 293 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 280 | 76 |
| Tramadol Hcl | Tramadol Hcl | 273 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 261 | 93 |
| Raloxifene Hcl | Raloxifene Hcl | 255 | 60 |
| Lorazepam | Lorazepam | 245 | 59 |
| Meloxicam | Meloxicam | 244 | 94 |
| Carvedilol | Carvedilol | 239 | 66 |
| Alprazolam | Alprazolam | 223 | 48 |
| Gabapentin | Gabapentin | 214 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 191 | 50 |
| Januvia | Sitagliptin Phosphate | 186 | 45 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 177 | 51 |
| Montelukast Sodium | Montelukast Sodium | 175 | 50 |
| Valsartan | Valsartan | 175 | 48 |
| Spironolactone | Spironolactone | 169 | 52 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 162 | 45 |
| Metformin Hcl Er | Metformin Hcl | 160 | 46 |
| Ozempic | Semaglutide | 160 | 27 |
| Glimepiride | Glimepiride | 157 | 49 |
| Azithromycin | Azithromycin | 154 | 127 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 52 |
| Mounjaro | Tirzepatide | 146 | 29 |
| Allopurinol | Allopurinol | 140 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 49 |
| Bupropion Xl | Bupropion Hcl | 138 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 137 | 50 |
| Cefdinir | Cefdinir | 136 | 113 |
| Donepezil Hcl | Donepezil Hcl | 136 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 136 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 34 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 133 | 37 |
| Sertraline Hcl | Sertraline Hcl | 133 | 29 |
| Potassium Chloride | Potassium Chloride | 131 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 39 |
| Atenolol | Atenolol | 121 | 34 |
| Ibuprofen | Ibuprofen | 113 | 42 |
| Jardiance | Empagliflozin | 113 | 35 |
| Clonazepam | Clonazepam | 111 | 15 |
| Ezetimibe | Ezetimibe | 111 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 58 |
| Glipizide Er | Glipizide | 105 | 31 |
| Buspirone Hcl | Buspirone Hcl | 102 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 97 | 42 |
| Alendronate Sodium | Alendronate Sodium | 94 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 27 |
| Nitroglycerin | Nitroglycerin | 94 | 72 |
| Xarelto | Rivaroxaban | 94 | 26 |
| Fenofibrate | Fenofibrate | 90 | 18 |
| Hydrocortisone | Hydrocortisone | 89 | 52 |
| Finasteride | Finasteride | 88 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 61 |
| Mirtazapine | Mirtazapine | 86 | 26 |
| Clobetasol Propionate | Clobetasol Propionate | 84 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 82 | 58 |
| Celecoxib | Celecoxib | 81 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 20 |
| Fluconazole | Fluconazole | 76 | 29 |
| Prednisone | Prednisone | 75 | 39 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 51 |
| Nifedipine Er | Nifedipine | 71 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 33 |
| Fluocinonide | Fluocinonide | 70 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 12 |
| Benazepril Hcl | Benazepril Hcl | 68 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 66 | 19 |
| Meclizine Hcl | Meclizine Hcl | 66 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 24 |
| Synthroid | Levothyroxine Sodium | 65 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 24 |
| Diazepam | Diazepam | 61 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 45 |
| Baclofen | Baclofen | 59 | 22 |
| Lovastatin | Lovastatin | 59 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 59 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 58 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 22 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 53 | 53 |
| Terazosin Hcl | Terazosin Hcl | 52 | 15 |
| Myrbetriq | Mirabegron | 51 | 17 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Valacyclovir | Valacyclovir Hcl | 47 | 27 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 15 |
| Lidocaine | Lidocaine | 44 | 18 |
| Nabumetone | Nabumetone | 44 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 41 | suppressed |
| Loperamide | Loperamide Hcl | 39 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | 12 |
| Enalapril Maleate | Enalapril Maleate | 38 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 38 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 32 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 35 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 32 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Ciclopirox | Ciclopirox | 27 | 13 |
| Etodolac | Etodolac | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 17 |
| Epinephrine | Epinephrine | 25 | 21 |
| Lactulose | Lactulose | 25 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Trimethoprim | Trimethoprim | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Estradiol | Estradiol | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | 18 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $899.49 · 46 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, Fluad, Flucelvax, JARDIANCE, KISUNLA, Kerendia, NEFFY, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error